SEC Form 4 · accession 0001179110-16-025108
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas H Aasen
Director
Period of report
May 18, 2016
Accepted (ET)
May 20, 2016 · 10:19 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $3.52 | May 18, 2016 | A | 8,357 | A | — | May 17, 2026 | Common Stock | 8,357 | 8,357 | D |
Explanation of responses
- F1The stock options will vest in full on May 18, 2017, subject to Mr. Aasen's continued service on such vesting date.